Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. has completed enrollment for a U.S. Phase IIa study of its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30, aimed at treating obesity. This milestone marks significant progress in the development of ASC30, which has demonstrated a 46-day half-life, supporting its potential as a once-monthly treatment option. Topline data from this study are expected in the first quarter of 2026, potentially impacting the company’s market positioning in obesity treatment.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a pharmaceutical company focused on developing innovative therapies, particularly in the field of obesity treatment. The company is known for its proprietary Ultra-Long-Acting Platform (ULAP) technology, which supports the development of long-acting treatment formulations.
Average Trading Volume: 9,437,429
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.08B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.